As a novel soluble guanylate cyclase stimulator, vericiguat can improve myocardial and vascular function, reduce ventricular remodeling, myocardial hypertrophy, inflammation and fibrosis, and delay the progression of heart failure by interfering with cell signaling pathways. Vericiguat not only can significantly reduce the risk of heart failure-related hospitalization or cardiovascular death, but also is well tolerated and compliant by patients, which can increase the additional benefit and improve prognosis of patients with heart failure with reduced ejection fraction. This article will review the mechanism and research progress of vericiguat in heart failure with reduced ejectionfraction.